Chronic Obstructive Pulmonary Disease
📧 Sign up to get email alerts when something new happens for Chronic Obstructive Pulmonary Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-06-05FDA Approved: DULERA — Supplemental Application (Organon LLC)
FDA approved a supplemental application for DULERA (mometasone furoate and formoterol fumarate dihydrate) from Organon LLC. The approval upd…
-
EMA approval · 2025-05-06EMA Authorised: Elebrato Ellipta (fluticasone furoate;umeclidinium bromide;vilanterol trifenatate) — GlaxoSmithKline Trading Services Limited
EMA authorized Elebrato Ellipta, a fixed-dose inhaled triple therapy for chronic obstructive pulmonary disease comprising fluticasone furoat…
-
EMA approval · 2025-05-05EMA Authorised: Trelegy Ellipta (fluticasone furoate;umeclidinium bromide;vilanterol trifenatate) — GlaxoSmithKline Trading Services Limited
EMA authorised Trelegy Ellipta (fluticasone furoate; umeclidinium bromide; vilanterol trifenatate) for chronic obstructive pulmonary disease…
-
FDA approval · 2025-04-25FDA Approved: ARFORMOTEROL TARTRATE INHALATION — Original Application (Devatis, Inc.)
FDA approved the original application for arformoterol tartrate inhalation by Devatis, Inc., a generic inhalation product for maintenance tr…
-
EMA approval · 2025-04-10EMA Authorised: Relvar Ellipta (fluticasone furoate;vilanterol) — GlaxoSmithKline Trading Services Limited
The EMA authorised Relvar Ellipta (fluticasone furoate and vilanterol) for chronic obstructive pulmonary disease; the product is manufacture…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-03-28EMA Authorised: Rolufta Ellipta (previously Rolufta) (umeclidinium bromide) — GlaxoSmithKline Trading Services Limited
The EMA authorised Rolufta Ellipta (umeclidinium bromide) for chronic obstructive pulmonary disease. The marketing authorization holder is G…
-
FDA approval · 2025-03-26FDA Approved: THEOPHYLLINE — Original Application (Ajanta Pharma USA Inc.)
FDA approves Ajanta Pharma USA Inc.'s original ANDA for theophylline, a bronchodilator used to treat symptoms of asthma and chronic obstruct…
-
FDA approval · 2025-03-14FDA Approved: ACETYLCYSTEINE — Original Application (Cameron Pharmaceuticals)
FDA approves Cameron Pharmaceuticals' Acetylcysteine original application (ANDA 214177). Acetylcysteine is used as a mucolytic and as an ant…
-
FDA approval · 2025-03-12FDA Approved: ALBUTEROL SULFATE INHALATION SOLUTION, 0.5% — Original Application (Ritedose Pharmaceuticals, LLC)
FDA approved ALBUTEROL SULFATE INHALATION SOLUTION, 0.5% from Ritedose Pharmaceuticals under an Abbreviated New Drug Application (generic). …
-
FDA approval · 2025-03-07FDA Approved: ARFORMOTEROL TARTRATE — Original Application (Micro Labs Limited)
The FDA approved a generic version of arformoterol tartrate (original application) for maintenance treatment of chronic obstructive pulmonar…
-
EMA approval · 2025-02-25EMA Authorised: Brimica Genuair (formoterol fumarate dihydrate;aclidinium bromide) — Covis Pharma Europe B.V.
The EMA authorized Brimica Genuair, a fixed-dose inhalation product containing formoterol fumarate dihydrate and aclidinium bromide, for chr…
-
EMA approval · 2025-02-25EMA Authorised: Bretaris Genuair (aclidinium bromide) — Covis Pharma Europe B.V.
The EMA authorised Bretaris Genuair (aclidinium bromide) for chronic obstructive pulmonary disease.
-
FDA approval · 2025-02-24FDA Approved: IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved the supplemental application from Sun Pharmaceutical for ipratropium bromide and albuterol sulfate, enabling the generic inhala…
-
EMA approval · 2025-02-18EMA Authorised: GoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) (Budesonide;formoterol fumarate dihydrate) — Teva Pharma B.V.
The European Medicines Agency authorised GoResp Digihaler, a budesonide/formoterol inhalation therapy by Teva Pharma B.V. (previously Budeso…
-
FDA approval · 2025-02-13FDA Approved: PREDNISOLONE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental Abbreviated New Drug Application for a generic prednisolone product from PAI Holdings/PAI Pharma, signaling regu…
-
FDA approval · 2025-02-12FDA Approved: ACETYLCYSTEINE — Original Application (Somerset Therapeutics, LLC)
FDA approved the original application for acetylcysteine from Somerset Therapeutics, LLC, granting approval for a generic acetylcysteine pro…
-
FDA approval · 2025-02-11FDA Approved: FORMOTEROL FUMARATE — Original Application (Devatis, Inc.)
FDA approved the original application (ANDA) for Formoterol Fumarate Dihydrate, the generic form of Formoterol Fumarate, manufactured by Dev…
-
FDA approval · 2025-02-07FDA Approved: IPRATROPIUM BROMIDE — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' generic ipratropium bromide (ANDA 217912), making a generic version of the drug available for approved C…
-
FDA approval · 2025-02-03FDA Approved: ARFORMOTEROL TARTRATE INHALATION SOLUTION — Original Application (Aucta Pharmaceuticals, Inc.)
FDA approved the original application for arformoterol tartrate inhalation solution, a generic inhaled long-acting beta-agonist for maintena…
-
FDA approval · 2025-01-31FDA Approved: ROFLUMILAST — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for roflumilast filed by Aurobindo Pharma Limited under ANDA213298, enabling a generic roflumila…
-
FDA approval · 2025-01-27FDA Approved: IPRATROPIUM BROMIDE — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approves Lupin Pharmaceuticals' original application for ipratropium bromide, a generic formulation of the anticholinergic bronchodilato…
-
FDA approval · 2025-01-14FDA Approved: IPRATROPIUM BROMIDE — Original Application (Advagen Pharma Ltd)
FDA approves an original application for ipratropium bromide from Advagen Pharma Ltd (ANDA 219222).
-
FDA approval · 2025-01-13FDA Approved: THEOPHYLLINE — Original Application (Ajanta Pharma USA Inc.)
FDA approves Ajanta Pharma USA's Theophylline as an original (generic) application; Theophylline is a bronchodilator for reversible airway o…
-
FDA approval · 2024-12-30FDA Approved: STIOLTO RESPIMAT — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for STIOLTO RESPIMAT (tiotropium bromide and olodaterol) from Boehringer Ingelheim Pharmaceuticals, …
-
FDA approval · 2024-12-27FDA Approved: STRIVERDI RESPIMAT — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approves a supplemental application for STRIVERDI RESPIMAT (olodaterol inhalation spray) from Boehringer Ingelheim Pharmaceuticals, …